<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686126</url>
  </required_header>
  <id_info>
    <org_study_id>feMMe</org_study_id>
    <nct_id>NCT01686126</nct_id>
  </id_info>
  <brief_title>Improving the Treatment for Women With Early Stage Cancer of the Uterus</brief_title>
  <acronym>feMMe</acronym>
  <official_title>A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queensland Centre for Gynaecological Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queensland University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queensland Centre for Gynaecological Cancer</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the standard treatment for early stage endometrial cancer or endometrial
      hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and
      removal of both ovaries. While highly effective, this surgery carries significant side
      effects for:

        -  young women who still wish to have children and would lose fertility; and

        -  women with one or more disorders (or diseases) in addition to the early stage
           endometrial cancer or endometrial hyperplasia with atypia and/or morbid obesity who are
           at risk for surgical complications making surgery unsafe.

      This study will access a new approach to the treatment of endometrial cancer to spare women
      of having to undergo major surgery that may be unwanted or unnecessary.

      Mirena is approved in Australia for contraception, to treat heavy bleeding, and to prevent
      thickening of the lining of the uterus (endometrial hyperplasia) during oestrogen
      replacement therapy (HRT). However it is not approved to treat early stage endometrial
      cancer or endometrial hyperplasia with atypia. This research project will test to see if
      Mirena is an effective treatment for early stage endometrial cancer and endometrial
      hyperplasia with atypia.

      Metformin is approved in Australia to treat Diabetes. However it is not approved to treat
      early stage endometrial cancer or endometrial hyperplasia with atypia. Therefore, it is an
      experimental treatment for early stage endometrial cancer and endometrial hyperplasia with
      atypia. This means that it must be tested to see if it is an effective treatment for early
      stage endometrial cancer and endometrial hyperplasia with atypia.

      Weight loss interventions are feasible and safe, and already being implemented by
      gynaecologic oncologist to make women eligible for surgery. Weight loss of 7% body weight
      induces a large biological effect (for example reduces incidence of diabetes by 58%, and
      hypertension by 26%).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predict the response to treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To predict the response to treatment through blood and tissue molecular biomarkers and to increase our molecular understanding of the biological pathogenesis of &quot;early&quot; EAC.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Complex Endometrial Hyperplasia With Atypia</condition>
  <condition>Grade 1 Endometrial Endometrioid Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Mirena + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirena + Weight Loss Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <arm_group_label>Mirena + Metformin</arm_group_label>
    <arm_group_label>Mirena</arm_group_label>
    <arm_group_label>Mirena + Weight Loss Intervention</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Mirena + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with a BMI &gt; 30 kg/m2 wishing to retain fertility or females who are at high
             risk of surgical complications due to co-morbidities or obesity

          2. Over 18 years of age at time of randomisation

          3. Histologically confirmed complex endometrial hyperplasia with atypia or grade 1
             endometrioid endometrial adenocarcinoma on a curette or endometrial biopsy

          4. CT scan of pelvis, abdomen and chest (or chest X-Ray) suggesting the absence of
             extrauterine disease

          5. Myometrial invasion on MRI of not more than 50%, for women with suspected
             histologically confirmed Endometrial Cancer only

          6. No lymph vascular invasion on curetting or pipelle

          7. Serum CA125 ≤ 30 U/mL

          8. No hypersensitivity or contraindications for mirena

          9. Ability to comply with endometrial biopsies at specified intervals

         10. Negative serum or urine pregnancy test in pre-menopausal women and women &lt; 2 years
             after the onset of menopause

         11. No Mirena® IUD or Mirena® IUD inserted &lt;  6 weeks prior to enrolment

        Exclusion Criteria:

          1. ECOG performance status &gt; 3

          2. Grade 1 endometrioid adenocarcinoma of the endometrium with myometrial invasion
             deeper than 50% on MRI or any patients with grade 2 or grade 3 endometrioid
             adenocarcinoma

          3. Histological (cell) type other than endometrioid adenocarcinoma (sarcomas or high
             risk endometrial e.g. papillary serous, clear cell)

          4. Pregnant or planning to become pregnant during trial period

          5. Prior treatment for EAC or EHA

          6. Patients with a history of pelvic or abdominal radiotherapy

          7. Unwilling to have additional endometrial biopsies or curettes or unable to attend
             three monthly clinical assessments

          8. Unable to provide informed consent or complete questionnaires

          9. Evidence of extrauterine spread on medical imaging

         10. Congenital or acquired uterine anomaly which distorts the uterine cavity

         11. Acute pelvic inflammatory disease

         12. Conditions associated with increased susceptibility to infections with microorganisms
             (e.g., AIDS, leukaemia, IV drug abuse) according to the patients Medical History

         13. Genital actinomycosis

         14. Current other cancer

         15. Breastfeeding mothers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Obermair</last_name>
    <role>Study Chair</role>
    <affiliation>Queensland Centre for Gynaecological Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pindarra Hospital</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brisbane Private Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Public Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Kawana Private Hospital</name>
      <address>
        <city>Sunshine Coast</city>
        <state>Queensland</state>
        <zip>4574</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Hospital Townsville</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Flynn Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Health Care North Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollywood Private Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial Hospital for Women</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6904</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 18, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial hyperplasia</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>Gynecological Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
